Atlas Trials

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Clinical trial NCT05436418 · RECRUITING

Trial details

NCT number
NCT05436418
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Peripheral Blood Stem Cell TransplantationHematopoietic Stem Cell Transplantation
Start date
2022-11-18
Primary completion
2027-06-25
Enrollment
260

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.